Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06594939 · ClinicalTrials.gov registry record · Phase 2
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Not yet
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT06594939 is a Phase 2 study that has not yet begun recruiting, run by Medical College of Wisconsin. The registered enrollment target is 31 participants.
The verdict
NCT06594939, a Phase 2 study, has not yet begun recruiting, sponsored by Medical College of Wisconsin.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This single-arm, interventional phase 2 study is designed to evaluate whether the inclusion of mosunetuzumab subcutaneous and polatuzumab vedotin (Mosun-Pola) to a split-dose CHP chemotherapy backbone will improve outcomes for elderly patients with a new diagnosis of diffuse large B-cell lymphoma.
Interventions
- DRUG Cyclophosphamide
- DRUG Mosunetuzumab
- DRUG Doxorubicin
- DRUG Prednisone
- DRUG Polatuzumab Vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06594939
The ClinicalTrials.gov registry entry for NCT06594939 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06594939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06594939 about?
NCT06594939 is a clinical study titled "Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma". This single-arm, interventional phase 2 study is designed to evaluate whether the inclusion of mosunetuzumab subcutaneous and polatuzumab vedotin (Mosun-Pola) to a split-dose CHP chemotherapy backbone will improve outcomes for elderly patients with a new diagnosis of diffuse large B-cell lymphoma.
What is the current status of trial NCT06594939?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2026-06. Estimated completion is 2029-12.
What interventions are being tested in trial NCT06594939?
The interventions under investigation include: Cyclophosphamide (DRUG), Mosunetuzumab (DRUG), Doxorubicin (DRUG), Prednisone (DRUG), Polatuzumab Vedotin (DRUG).
Who is sponsoring clinical trial NCT06594939?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.